The history of the erectile dysfunction drug presents a challenging picture for shareholders. While the initial release generated significant gains, the expiration of its patent opened the door to off-brand versions, https://bookmarketmaven.com/story22512462/sildenafil-and-big-pharma-a-precarious-opportunity